It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed in 2016.[5] Researchers at the University of Leeds and Novo Nordisk reported in 2017 that it can also be used for the treatment of obesity.[6] It reduces hunger, food craving and body fat.[7] FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour.[8] On December 5, 2017, semaglutide was approved by the US FDA
Very high doses (above this) have not been well studied
Keeping up a regular routine of cleansing, exfoliating and moisturizing with products specifically designed to tread KP is your best bet, but it won't happen overnight
That gap is exactly why the compound is sold for research only
According to the quantitative results, both the BV/TV and Tb.N were significantly optimized in the GH@LM + GA@HLM (G4) group (Fig
Some patients may benefit from slower dose escalation or temporary dose reduction of their GLP-1 medication if constipation becomes problematic, though this should only occur under medical supervision